DBV Technologies
Develops epicutaneous immunotherapy (EPIT) patch technology for food allergies.
DBV | PA
Overview
Corporate Details
- ISIN(s):
- FR0010417345 (+3 more)
- LEI:
- 969500PVBQFWQKVDMD80
- Country:
- France
- Address:
- 107 AVENUE DE LA REPUBLIQUE, 92320 CHATILLON
- Sector:
- Manufacturing
Description
DBV Technologies is a clinical-stage biopharmaceutical company developing treatments for food allergies and other immunological diseases. The company's core technology is Viaskin®, a proprietary investigational platform based on epicutaneous immunotherapy (EPIT). This non-invasive patch technology is designed to re-educate the immune system by delivering minimal amounts of antigens through intact skin. DBV's lead product candidate, Viaskin Peanut (DBV712), is in late-stage clinical development for the treatment of peanut allergies in pediatric patients. The development pipeline also includes Viaskin Milk (DBV135) for milk allergies, with the platform holding potential for applications beyond food allergies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-03-17 23:30 |
DBV Technologies Announces Filing of 2020 Annual Report on Form 10-K and 2020 U…
|
English | 180.7 KB | ||
| 2021-03-17 15:30 |
Document d'Enregistrement Universel 2020
|
French | 2.6 MB | ||
| 2021-03-12 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions…
|
French | 97.1 KB | ||
| 2021-03-12 22:30 |
Monthly information regarding the total number of voting rights and total numbe…
|
English | 160.3 KB | ||
| 2021-03-11 22:30 |
DBV Technologies annonce ses résultats financiers pour l’exercice 2020 et fait …
|
French | 332.8 KB | ||
| 2021-03-11 22:30 |
DBV Technologies Reports Full-Year 2020 Financial Results and Recent Business D…
|
English | 294.1 KB | ||
| 2021-03-05 22:30 |
DBV Technologies invitée à participer à la H.C. Wainwright Global Life Sciences…
|
French | 178.1 KB | ||
| 2021-03-05 22:30 |
DBV Technologies to Participate in the H.C. Wainwright Global Life Sciences Con…
|
English | 132.6 KB | ||
| 2021-03-04 00:00 |
DBV Technologies Announces Date Change for Reporting Full Year 2020 Financial R…
|
English | 199.8 KB | ||
| 2021-03-04 00:00 |
DBV Technologies annonce un changement de date pour la publication de ses résul…
|
French | 200.4 KB | ||
| 2021-03-01 07:30 |
DBV Technologies présente ses résultats financiers pour l’exercice 2020
|
French | 200.0 KB | ||
| 2021-03-01 07:30 |
DBV Technologies to Report Full Year 2020 Financial Results on March 4, 2021
|
English | 199.6 KB | ||
| 2021-02-24 07:30 |
DBV Technologies participera au prochain congrès de l’AAAAI 2021
|
French | 230.2 KB | ||
| 2021-02-24 07:30 |
DBV Technologies to Participate in Upcoming AAAAI 2021 Congress
|
English | 247.0 KB | ||
| 2021-02-22 07:30 |
DBV Technologies annonce la nomination de Michele F. Robertson au poste de Dire…
|
French | 216.9 KB |
Automate Your Workflow. Get a real-time feed of all DBV Technologies filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for DBV Technologies
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for DBV Technologies via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-09 | N/A | Other | Other | 2,483,161 | 7,449,483.00 EUR |
Peer Companies
